Subscribe to RSS
DOI: 10.1055/s-0029-1234147
New Anticoagulants for Atrial Fibrillation
Publication History
Publication Date:
08 September 2009 (online)
![](https://www.thieme-connect.de/media/sth/200905/lookinside/thumbnails/10.1055-s-0029-1234147-1.jpg)
ABSTRACT
Atrial fibrillation is already the most common clinically significant cardiac arrhythmia and a common cause of stroke. Vitamin K antagonists are very effective for the prevention of cardioembolic stroke but have numerous limitations that limit their uptake in eligible patients with AF and reduce their effectiveness in treated patients. Multiple new anticoagulants are under development as potential replacements for vitamin K antagonists. Most are small synthetic molecules that target factor IIa (e.g., dabigatran etexilate, AZD-0837) or factor Xa (e.g., rivaroxaban, apixaban, betrixaban, DU176b, idrabiotaparinux). These drugs have minimal protein binding and predictable pharmacokinetics that allow fixed dosing without laboratory monitoring and are being compared with vitamin K antagonists or aspirin in phase III clinical trials. A new vitamin K antagonist (ATI-5923) with improved pharmacological properties compared with warfarin is also being evaluated in a phase III trial. None of the new agents have as yet been approved for clinical use.
KEYWORDS
Atrial fibrillation - anticoagulants - stroke - factor Xa inhibitor - direct thrombin inhibitor
REFERENCES
- 1 Go A S, Hylek E M, Phillips K A et al.. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001; 285(18) 2370-2375
- 2 Miyasaka Y, Barnes M E, Gersh B J et al.. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006; 114(2) 119-125
- 3 Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994; 154(13) 1449-1457
- 4 Wolf P A, Abbott R D, Kannel W B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991; 22(8) 983-988
- 5 Dulli D A, Stanko H, Levine R L. Atrial fibrillation is associated with severe acute ischemic stroke. Neuroepidemiology. 2003; 22(2) 118-123
- 6 Lin H J, Wolf P A, Kelly-Hayes M et al.. Stroke severity in atrial fibrillation. The Framingham Study. Stroke. 1996; 27(10) 1760-1764
- 7 Wolf P A, Mitchell J B, Baker C S, Kannel W B, D’Agostino R B. Impact of atrial fibrillation on mortality, stroke, and medical costs. Arch Intern Med. 1998; 158(3) 229-234
- 8 Hart R G, Pearce L A, Aguilar M I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007; 146(12) 857-867
- 9 Lip G Y, Edwards S J. Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. Thromb Res. 2006; 118(3) 321-333
- 10 Glazer N L, Dublin S, Smith N L et al.. Newly detected atrial fibrillation and compliance with antithrombotic guidelines. Arch Intern Med. 2007; 167(3) 246-252
- 11 Hart R G, Benavente O, McBride R, Pearce L A. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999; 131(7) 492-501
- 12 Albers G W, Dalen J E, Laupacis A, Manning W J, Petersen P, Singer D E. Antithrombotic therapy in atrial fibrillation. Chest. 2001; 119(1, suppl) 194S-206S
- 13 Go A S, Hylek E M, Borowsky L H, Phillips K A, Selby J V, Singer D E. Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study. Ann Intern Med. 1999; 131(12) 927-934
- 14 Go A S, Hylek E M, Chang Y et al.. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice?. JAMA. 2003; 290(20) 2685-2692
- 15 McCormick D, Gurwitz J H, Goldberg R J et al.. Prevalence and quality of warfarin use for patients with atrial fibrillation in the long-term care setting. Arch Intern Med. 2001; 161(20) 2458-2463
- 16 Bradley B C, Perdue K S, Tisdel K A, Gilligan D M. Frequency of anticoagulation for atrial fibrillation and reasons for its non-use at a Veterans Affairs medical center. Am J Cardiol. 2000; 85(5) 568-572
- 17 Bungard T J, Ghali W A, Teo K K, McAlister F A, Tsuyuki R T. Why do patients with atrial fibrillation not receive warfarin?. Arch Intern Med. 2000; 160(1) 41-46
- 18 Jones M, McEwan P, Morgan C L, Peters J R, Goodfellow J, Currie C J. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population. Heart. 2005; 91(4) 472-477
- 19 Rose A J, Ozonoff A, Henault L E, Hylek E M. Warfarin for atrial fibrillation in community-based practise. J Thromb Haemost. 2008; 6(10) 1647-1654
- 20 Shalev V, Rogowski O, Shimron O et al.. The interval between prothrombin time tests and the quality of oral anticoagulants treatment in patients with chronic atrial fibrillation. Thromb Res. 2007; 120(2) 201-206
- 21 Hylek E M, Go A S, Chang Y et al.. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003; 349(11) 1019-1026
- 22 White H D, Gruber M, Feyzi J et al.. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control: results from SPORTIF III and V. Arch Intern Med. 2007; 167(3) 239-245
- 23 Wienen W, Stassen J M, Priepke H, Ries U J, Hauel N. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate. Thromb Haemost. 2007; 98(1) 155-162
- 24 Stangier J, Rathgen K, Stähle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007; 64(3) 292-303
- 25 Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet. 2008; 47(5) 285-295
- 26 Sanford M, Plosker G L. Dabigatran etexilate. Drugs. 2008; 68(12) 1699-1709
- 27 Eriksson B I, Dahl O E, Rosencher N RE-MODEL Study Group et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost. 2007; 5(11) 2178-2185
- 28 Eriksson B I, Dahl O E, Rosencher N RE-NOVATE Study Group et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007; 370(9591) 949-956
- 29 Ginsberg J S, Davidson B L, Comp P C RE-MOBILIZE Writing Committee et al. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009; 24(1) 1-9
- 30 Ezekowitz M D, Reilly P A, Nehmiz G et al.. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study). Am J Cardiol. 2007; 100(9) 1419-1426
- 31 Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939—an oral, direct Factor Xa inhibitor—after multiple dosing in healthy male subjects. Eur J Clin Pharmacol. 2005; 61(12) 873-880
- 32 Weinz C, Schwartz T, Pleiss U. Metabolism and distribution of (14C) BAY 59-7939—an oral, direct factor Xa inhibitor—in rat, dog and human [abstract 196]. Drug Metab Rev. 2004; 36(suppl 1)
- 33 Eriksson B I, Quinlan D J, Weitz J I. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor xa inhibitors in development. Clin Pharmacokinet. 2009; 48(1) 1-22
- 34 Kakkar A K, Brenner B, Dahl O E RECORD2 Investigators et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet. 2008; 372(9632) 31-39
- 35 Eriksson B I, Borris L C, Friedman R J RECORD1 Study Group et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008; 358(26) 2765-2775
- 36 Lassen M R, Ageno W, Borris L C RECORD3 Investigators et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008; 358(26) 2776-2786
- 37 Turpie A, Bauer K, Davidson B et al.. Comparison of ‘Xarelto’—an oral, direct factor Xa inhibitor and subcutaneous enoxaparin for thromboprophylaxis after total knee replacement (RECORD4: a phase 3 study). Paper presented at: European Federation of National Associations of Orthopaedics and Traumatology annual meeting May 29–June 1, 2008 Nice, France; Abstract F85
- 38 Frost C, Yu Z, Nepal S. Apixaban, a direct factor Xa inhibitor: single-dose pharmacokinetics and pharmacodynamics of an intravenous formulation. Paper presented at: 37th American College of Chest Physicians annual meeting September 14–16, 2008 Philadelphia, PA;
- 39 Raghavan N, Frost C E, Yu Z et al.. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos. 2009; 37(1) 74-81
- 40 Lassen M R, Davidson B L, Gallus A, Pineo G, Ansell J, Deitchman D. The efficacy and safety of apixaban, an oral, direct factor Xa inhibitor, as thromboprophylaxis in patients following total knee replacement. J Thromb Haemost. 2007; 5(12) 2368-2375
- 41 Buller H R. Late breaking clinical trial: a dose finding study of the oral direct factor xa inhibitor apixaban in the treatment of patients with acute symptomatic deep vein thrombosis – The Botticelli Investigators. J Thromb Haemost. 2007; 5(suppl 2) , Abstract S-003
- 42 Zafar M U, Vorchheimer D A, Gaztanaga J et al.. Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber. Thromb Haemost. 2007; 98(4) 883-888
- 43 Walenga J M, Jeske W P, Fareed J. Short- and long-acting synthetic pentasaccharides as antithrombotic agents. Expert Opin Investig Drugs. 2005; 14(7) 847-858
- 44 Herbert J M, Hérault J P, Bernat A et al.. Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood. 1998; 91(11) 4197-4205
- 45 Trellu M, Perez Y, Ortiz J, Cheng S, Paty I. Bioequipotency of idraparinux and biotinylated idraparinux after single dose in healthy subjects. , [Abstract P-T-678] J Thromb Haemost. 2007; 5(suppl 1) , Abstract P-T-678
- 46 Buller H R, Destors J, Gallus A S, Prins M H, Raskob G E. Idrabiotaparinux, a biotinylated long-acting anticoagulant, in the treatment of deep venous thrombosis (EQUINOX study): safety, efficacy, and reversibility by avidin. Paper presented at: American Society of Hematology 2008 San Francisco, CA;
- 47 Buller H R, Cohen A T, Davidson B van Gogh Investigators et al. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med. 2007; 357(11) 1094-1104
- 48 Bousser M G, Bouthier J, Büller H R Amadeus Investigators et al. Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. Lancet. 2008; 371(9609) 315-321
- 49 Ezekowitz M D, Milner P, Ellis D et al.. The utility of genotyping in the first evaluation of a novel vitamin K antagonist: ATI-5923. Circulation. 2008; 118(Suppl 885) , Abstract 4415
Dr. Magdalena Sobieraj-Teague
Hamilton General Hospital
Level 7, Room 714, 237 Barton Street East, Hamilton, Ontario, L8L 2X2 Canada
Email: teaguem@mcmaster.ca